COMPARE · Data as of August 24, 2026

SOLS vs STDN

Verdict: Side-by-side breakdown using the Bull Rankings model. SOLS scored 55.2, STDN scored 44.8 — SOLS leads.
Compare another set
SOLS
Solstice Advanced Materials, Inc.
Specialty Chemicals · Quality-Growth
55.2
$55.36 · $8.8B
fundamentals as of
Score gap
10.4
SOLS leads
STDN
Standard Nuclear, Inc.
Specialty Chemicals · Quality-Growth
44.8
$11.94 · $1.9B
  • Fastest growthSTDN+57.1%
  • Highest qualitySOLS51 / 100
THE BULL RANKINGS SCORECARD55.2/ 100 · BULL SCOREPEER MEDIANQUALITY51.4GROWTH50.0VALUE65.3
THE BULL RANKINGS SCORECARD44.8/ 100 · BULL SCOREPEER MEDIANQUALITY45.0GROWTH50.0VALUE40.0
SOLSSTDNQuality51.445.0Growth50.050.0Value65.340.0
RevSOLS+9.2%STDN+57.1%
SOLS
stronger →← stronger
STDN
51
Qualityreturns · margins · balance sheet
45
50
Growthrevenue & earnings expansion
50
65
Valuevaluation vs sector peers
40
SOLS is stronger on 2 of 3 pillars.
SOLS
STDN
$195mC
FCF
+9.2%B
Rev
+57.1%A
1.53D
D/E
42.6xC
P/E
0.62A-
PEG
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
SOLS
STDN
130% above
Price vs fair valuelower is cheaper
~32%/yr
Growth the price implies10-yr FCF · lower = less priced in
-63%
1-yr DCF upside
-57%
5-yr DCF upside
-45%
10-yr DCF upside
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
SOLS
Why this score
  • Cyclical growth
  • Short track record
STDN
Why this score
  • Cyclical growth
  • Short track record
SOLSSolstice Advanced Materials, Inc.
Specialty Chemicals · $55.36
Why now
Specialty Chemicals · market cap $8.8b. Down 39% from 52-week high of $90.80 — deep drawdown territory. PEG 0.62 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $80.43 (implying +45% upside).
Moat
ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere.
Risk
Down 39% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 43x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
STDNStandard Nuclear, Inc.
Specialty Chemicals · $11.94
Why now
Specialty Chemicals · market cap $1.9b. 15% off the 52-week high of $13.98. Revenue growing +57% — in hypergrowth territory. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $16.00 (implying +34% upside).
Moat
Higher-variance name — the moat signals on the quantitative card are modest, so the durability case rests on execution (turning current growth into durable earnings power) or an un-monetized asset (IP / network effects / first-mover position) rather than an entrenched competitive position.
Risk
Higher-variance name — the thesis leans on growth and valuation rather than a long, settled track record, so it depends on execution continuing. Position size accordingly; a deep drawdown shouldn't change the thesis.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where SOLS and STDN diverge

On the headline score the gap is 10.4 points in favor of SOLS. The widest single difference is Value, where SOLS leads by 25.3 points.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.